Antibody Journal
Articles about Antibody Journal (0)
-
Why Promising Antibody Candidates Fail Before Clinical Trials – and How to Avoid It
Despite strong market growth, most antibody candidates fail early due to developability, pharmacokinetics, or immunogenicity issues. This article outlines key risks and strategies to de-risk development and speed the path from discovery to IND.
-
Fast-Tracking Bispecific Antibody Development: What Can Go Wrong?
Bispecific antibodies hold great promise, but rushing development can trigger design and manufacturing risks. This article explores how smart strategies and expert partnerships accelerate bsAb programs without compromising quality.
-
The Risks of Over-Promising in Early-Stage Biologics Development
In early biologics development, over-promising can derail programs and erode trust. This article explores the causes, consequences, and how data-driven planning safeguards progress and credibility.
-
The Stability Problem: Why Some Recombinant Antibodies Don’t Make It to Market
Stability is key to antibody success, but physical, chemical, and biological issues often derail candidates. This article covers causes, consequences, and strategies to improve stability, manufacturability, and speed development to market.
-
Afucosylated recombinant antibodies
Generally speaking, antibodies of any kind, including recombinant and afucosylated antibodies, are Y-shaped proteins produced by the human body. As they are able to identify and neutralize foreign objects – in other words viruses – they play a major contributing role in keeping our body and immune system healthy.
-
Bispecific Antibodies: A Comprehensive Overview
BsAbs are a comparatively new and extremely promising class of antibodies. In this article, we provide an overview of bispecific antibodies, including their mechanism of action and expressions.
-
Understanding the side effects of bispecific antibodies
Despite the enormous progress that has been made in the field of bsAbs, the side effects related to their administration have to be considered as well. In this article, we provide a general overview of possible side effects.
-
FDA approved bispecific antibodies
Especially in the past decade, the FDA has approved several bispecific antibody (bsAb) products, revolutionizing the treatment of myriad medical conditions. In this article, we will take a look at the bsAbs currently approved by the FDA.
-
Bispecific antibody companies: What companies are developing bispecific drug products?
The bispecific antibody (bsAb) market is shaped by several key players that have been changing the way severe diseases can be treated. We will talk about some of them in this article.
-
Applications of bispecific antibodies in therapeutics
Bispecific antibodies are already being used in a considerable number of therapeutic applications, which are believed to further increase in the coming years. We will discuss them in this article.
